Because of the lymphodepleting chemotherapy, persistent B-cell aplasia, hypogammaglobulinemia, and CRS, patients who received CD19-CAR-T therapy had high risk of infections, especially the viral kind. Here, CD19 is linked to congenital rubella syndrome.